Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional studyLothar Bergmann, Michael Staehler, Ulrich Kube et al.|BMC Cancer|2015Cited by 23
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysisLuise Maute, Lothar Bergmann, Viktor Grünwald et al.|Journal of Cancer Research and Clinical Oncology|2014Cited by 16
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional StudyLothar Bergmann, Christian Doehn, Steffen Weikert et al.|Oncology Research and Treatment|2013Cited by 15
Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.Peter J. Goebell, Lothar Bergmann, Ulrich Kube et al.|Journal of Clinical Oncology|2014Cited by 5
Updated results of a prospective noninterventional study of everolimus after use of 1 VEGFR-TKI.Lothar Bergmann, Christian Doehn, Peter J. Goebell et al.|Journal of Clinical Oncology|2012Cited by 1